{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:24:49Z","timestamp":1707524689518},"reference-count":42,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,6]]},"DOI":"10.7759\/cureus.26600","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T08:00:11Z","timestamp":1657094411000},"source":"Crossref","is-referenced-by-count":0,"title":["Assessing the Efficacy of Alkylating Agent Regimens in the Treatment of Infantile Malignant Osteopetrosis: Cyclophosphamide, Busulfan, or Thiotepa"],"prefix":"10.7759","author":[{"given":"Himanshu","family":"Wagh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amber","family":"Arif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akshay J","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ethan","family":"Tabaie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditya","family":"Shekhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mildred","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neel","family":"Nawathey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Bachir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hetal","family":"Brahmbhatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4103\/0971-6866.112911","article-title":"Malignant infantile osteopetrosis","volume":"19","author":"Kumar KJ","year":"2013","unstructured":"Kumar KJ, Bandaru K, Prashanth SN, Mamatha S. Malignant infantile osteopetrosis. Indian J Hum Genet. 2013, 19:90-2. 10.4103\/0971-6866.112911","journal-title":"Indian J Hum Genet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.6725","article-title":"Malignant infantile osteopetrosis: a case report","volume":"12","author":"Bubshait DK","year":"2020","unstructured":"Bubshait DK, Himdy ZE, Fadaaq O, Alshmas HI. Malignant infantile osteopetrosis: a case report. Cureus. 2020, 12:10.7759\/cureus.6725","journal-title":"Cureus"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-01127","article-title":"Diagnosis and management of osteopetrosis: consensus guidelines from the osteopetrosis working group","volume":"102","author":"Wu CC","year":"2017","unstructured":"Wu CC, Econs MJ, DiMeglio LA, et al.. Diagnosis and management of osteopetrosis: consensus guidelines from the osteopetrosis working group. J Clin Endocrinol Metab. 2017, 102:3111-23. 10.1210\/jc.2017-01127","journal-title":"J Clin Endocrinol Metab"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018025890","article-title":"Stem cell transplantation for osteopetrosis in patients beyond the age of 5 years","volume":"3","author":"Stepensky P","year":"2019","unstructured":"Stepensky P, Grisariu S, Avni B, et al.. Stem cell transplantation for osteopetrosis in patients beyond the age of 5 years. Blood Adv. 2019, 3:862-8. 10.1182\/bloodadvances.2018025890","journal-title":"Blood Adv"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01955-6","article-title":"Haploidentical haematopoietic stem cell transplantation for malignant infantile osteopetrosis and intermediate osteopetrosis: a retrospective analysis of a single centre","volume":"16","author":"Zhu G","year":"2021","unstructured":"Zhu G, Wei A, Wang B, et al.. Haploidentical haematopoietic stem cell transplantation for malignant infantile osteopetrosis and intermediate osteopetrosis: a retrospective analysis of a single centre. Orphanet J Rare Dis. 2021, 16:10.1186\/s13023-021-01955-6","journal-title":"Orphanet J Rare Dis"},{"key":"ref6","article-title":"Graft versus host disease","author":"Justiz Vaillant AA","year":"2021","unstructured":"Justiz Vaillant AA, Modi P, Mohammadi O. Graft versus host disease. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2021."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v99.9.3458","article-title":"HLA-haploidentical blood progenitor cell transplantation in osteopetrosis","volume":"99","author":"Schulz AS","year":"2002","unstructured":"Schulz AS, Classen CF, Mihatsch WA, et al.. HLA-haploidentical blood progenitor cell transplantation in osteopetrosis. Blood. 2002, 99:3458-60. 10.1182\/blood.v99.9.3458","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01040-9","article-title":"Haploidentical stem cell transplantation with post-transplant cyclophosphamide for osteopetrosis and other nonmalignant diseases","volume":"56","author":"Even-Or E","year":"2021","unstructured":"Even-Or E, NaserEddin A, Dinur Schejter Y, Shadur B, Zaidman I, Stepensky P. Haploidentical stem cell transplantation with post-transplant cyclophosphamide for osteopetrosis and other nonmalignant diseases. Bone Marrow Transplant. 2021, 56:434-41. 10.1038\/s41409-020-01040-9","journal-title":"Bone Marrow Transplant"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-625541","article-title":"Hematopoietic stem cell transplantation for infantile osteopetrosis","volume":"126","author":"Orchard PJ","year":"2015","unstructured":"Orchard PJ, Fasth AL, Le Rademacher J, et al.. Hematopoietic stem cell transplantation for infantile osteopetrosis. Blood. 2015, 126:270-6. 10.1182\/blood-2015-01-625541","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1080\/08880010701773621","article-title":"Allogeneic hematopoietic stem cell transplantation using a reduced-intensity conditioning regimen in infants: experience at a single institution in Mexico","volume":"25","author":"Llano OG","year":"2008","unstructured":"Llano OG, Perez JC, Rodriguez OC, et al.. Allogeneic hematopoietic stem cell transplantation using a reduced-intensity conditioning regimen in infants: experience at a single institution in Mexico. Pediatr Hematol Oncol. 2008, 25:39-47. 10.1080\/08880010701773621","journal-title":"Pediatr Hematol Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01282-1","article-title":"T-cell replete haploidentical transplantation with reduced post-transplant cyclophosphamide in six children with infantile osteopetrosis","volume":"56","author":"Al-Seraihy A","year":"2021","unstructured":"Al-Seraihy A, Al-Saedi H, Al-Ahmari A, Ghemlas I, Ayas M. T-cell replete haploidentical transplantation with reduced post-transplant cyclophosphamide in six children with infantile osteopetrosis. Bone Marrow Transplant. 2021, 56:1757-60. 10.1038\/s41409-021-01282-1","journal-title":"Bone Marrow Transplant"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(83)91438-1","article-title":"Allogeneic bone-marrow transplantation in infantile malignant osteopetrosis","volume":"321","author":"Sieff CA","year":"1983","unstructured":"Sieff CA, Chessells JM, Levinsky RJ, et al.. Allogeneic bone-marrow transplantation in infantile malignant osteopetrosis. Lancet. 1983, 321:437-4. 10.1016\/s0140-6736(83)91438-1","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(86)90465-4","article-title":"Prevention of graft failure by an anti-HLFA-1 monoclonal antibody in HLA-mismatched bone-marrow transplantation","volume":"8","author":"Fischer A","year":"1986","unstructured":"Fischer A, Griscelli C, Blanche S, et al.. Prevention of graft failure by an anti-HLFA-1 monoclonal antibody in HLA-mismatched bone-marrow transplantation. Lancet. 1986, 8:1058-61. 10.1016\/s0140-6736(86)90465-4","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3046.2006.00537.x","article-title":"Successful unrelated mismatched cord blood transplantation in a child with malignant infantile osteopetrosis","volume":"10","author":"Jaing TH","year":"2006","unstructured":"Jaing TH, Hou JW, Chen SH, Huang IA, Wang CJ, Lee WI. Successful unrelated mismatched cord blood transplantation in a child with malignant infantile osteopetrosis. Pediatr Transplant. 2006, 10:629-31. 10.1111\/j.1399-3046.2006.00537.x","journal-title":"Pediatr Transplant"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.180","article-title":"Haploidentical transplantation with post-transplant cyclophosphamide following reduced-intensity conditioning for osteopetrosis: outcomes in three children","volume":"51","author":"Bahr TL","year":"2016","unstructured":"Bahr TL, Lund T, Sando NM, Orchard PJ, Miller WP. Haploidentical transplantation with post-transplant cyclophosphamide following reduced-intensity conditioning for osteopetrosis: outcomes in three children. Bone Marrow Transplant. 2016, 51:1546-8. 10.1038\/bmt.2016.180","journal-title":"Bone Marrow Transplant"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/petr.12476","article-title":"Non-total body irradiation myeloablative conditioning with intravenous busulfan and cyclophosphamide in hematopoietic stem cell transplantation for malignant infantile osteopetrosis","volume":"19","author":"Behfar M","year":"2015","unstructured":"Behfar M, Dehghani SS, Hosseini AS, Jalali A, Hamidieh AA, Ghavamzadeh A. Non-total body irradiation myeloablative conditioning with intravenous busulfan and cyclophosphamide in hematopoietic stem cell transplantation for malignant infantile osteopetrosis. Pediatr Transplant. 2015, 19:422-7. 10.1111\/petr.12476","journal-title":"Pediatr Transplant"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704456","article-title":"Thyroid dysfunction after bone marrow transplantation for primary immunodeficiency without the use of total body irradiation in conditioning","volume":"33","author":"Slatter MA","year":"2004","unstructured":"Slatter MA, Gennery AR, Cheetham TD, et al.. Thyroid dysfunction after bone marrow transplantation for primary immunodeficiency without the use of total body irradiation in conditioning. Bone Marrow Transplant. 2004, 33:949-53. 10.1038\/sj.bmt.1704456","journal-title":"Bone Marrow Transplant"},{"key":"ref18","article-title":"Allogeneic stem cell transplantation for 8 patients with malignant infantile osteopetrosis in China. [Article in Chinese]","volume":"50","author":"Zhu GH","year":"2012","unstructured":"Zhu GH, Qin MQ, Wang B, et al.. Allogeneic stem cell transplantation for 8 patients with malignant infantile osteopetrosis in China. [Article in Chinese]. Zhonghua Er Ke Za Zhi. 2012, 50:807-12.","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13536","article-title":"Haploidentical transplantation in pediatric non-malignant diseases: A retrospective analysis on behalf of the Spanish Group for Hematopoietic Transplantation (GETH)","volume":"106","author":"Torres Canizales J","year":"2021","unstructured":"Torres Canizales J, Ferreras C, Pascual A, et al.. Haploidentical transplantation in pediatric non-malignant diseases: A retrospective analysis on behalf of the Spanish Group for Hematopoietic Transplantation (GETH). Eur J Haematol. 2021, 106:196-204. 10.1111\/ejh.13536","journal-title":"Eur J Haematol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701758","article-title":"The role of thiotepa in allogeneic bone marrow transplantation for genetic diseases","volume":"23","author":"Rosales F","year":"1999","unstructured":"Rosales F, Peylan-Ramu N, Cividalli G, et al.. The role of thiotepa in allogeneic bone marrow transplantation for genetic diseases. Bone Marrow Transplant. 1999, 23:861-5. 10.1038\/sj.bmt.1701758","journal-title":"Bone Marrow Transplant"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199511000-00013","article-title":"Bone marrow transplantation for infantile malignant osteopetrosis","volume":"17","author":"Solh H","year":"1995","unstructured":"Solh H, Da Cunha AM, Giri N, et al.. Bone marrow transplantation for infantile malignant osteopetrosis. J Pediatr Hematol Oncol. 1995, 17:350-5. 10.1097\/00043426-199511000-00013","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref22","article-title":"Mild autosomal recessive osteopetrosis: successful treatment with bone marrow transplant","volume":"64","author":"Othman IS","year":"2009","unstructured":"Othman IS, Ibrahim H, Hii KC, Ong GB, Menon BS. Mild autosomal recessive osteopetrosis: successful treatment with bone marrow transplant. Med J Malaysia. 2009, 64:325-6.","journal-title":"Med J Malaysia"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.03.009","article-title":"Haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide for primary immunodeficiencies and inherited disorders in children","volume":"25","author":"Neven B","year":"2019","unstructured":"Neven B, Diana JS, Castelle M, et al.. Haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide for primary immunodeficiencies and inherited disorders in children. Biol Blood Marrow Transplant. 2019, 25:1363-73. 10.1016\/j.bbmt.2019.03.009","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198003273021301","article-title":"Successful bone-marrow transplantation for infantile malignant osteopetrosis","volume":"302","author":"Coccia PF","year":"1980","unstructured":"Coccia PF, Krivit W, Cervenka J, et al.. Successful bone-marrow transplantation for infantile malignant osteopetrosis. N Engl J Med. 1980, 302:701-8. 10.1056\/NEJM198003273021301","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-013-1405-x","article-title":"Effect of HLA mismatch on acute graft-versus-host disease","volume":"98","author":"Kanda J","year":"2013","unstructured":"Kanda J. Effect of HLA mismatch on acute graft-versus-host disease. Int J Hematol. 2013, 98:300-8. 10.1007\/s12185-013-1405-x","journal-title":"Int J Hematol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.05.017","article-title":"The national marrow donor program 20 years of unrelated donor hematopoietic cell transplantation","volume":"14","author":"Ballen KK","year":"2008","unstructured":"Ballen KK, King RJ, Chitphakdithai P, Bolan CD Jr, Agura E, Hartzman RJ, Kernan NA. The national marrow donor program 20 years of unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008, 14:2-7. 10.1016\/j.bbmt.2008.05.017","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.09.017","article-title":"Recommendations for donor human leukocyte antigen assessment and matching for allogeneic stem cell transplantation: consensus opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)","volume":"21","author":"Howard CA","year":"2015","unstructured":"Howard CA, Fernandez-Vina MA, Appelbaum FR, et al.. Recommendations for donor human leukocyte antigen assessment and matching for allogeneic stem cell transplantation: consensus opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant. 2015, 21:4-7. 10.1016\/j.bbmt.2014.09.017","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref28","article-title":"Cyclophosphamide","author":"Ogino MH","year":"2021","unstructured":"Ogino MH, Tadi P. Cyclophosphamide. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2021."},{"key":"ref29","article-title":"Busulfan","author":"Patel R","year":"2021","unstructured":"Patel R, Tadi P. Busulfan. StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL; 2021."},{"key":"ref30","article-title":"Thiotepa","year":"2020","unstructured":"Thiotepa. LiverTox. Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD; 2020."},{"key":"ref31","article-title":"Melphalan","year":"2012","unstructured":"Melphalan. Pharmaceuticals. International Agency for Research on Cancer, Lyon, France; 2012."},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3109\/10428199309047886","article-title":"Busulfan and cyclophosphamide versus cyclophosphamide and total body irradiation for marrow transplantation in chronic myelogenous leukemia--a review","volume":"11","author":"Santos GW","year":"1993","unstructured":"Santos GW. Busulfan and cyclophosphamide versus cyclophosphamide and total body irradiation for marrow transplantation in chronic myelogenous leukemia--a review. Leuk Lymphoma. 1993, 11:201-4. 10.3109\/10428199309047886","journal-title":"Leuk Lymphoma"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.5144\/1658-3876.2011.17","article-title":"Cyclophosphamide plus total body irradiation compared with busulfan plus cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplantation in patients with leukemia: a systematic review and meta-analysis","volume":"4","author":"Gupta T","year":"2011","unstructured":"Gupta T, Kannan S, Dantkale V, Laskar S. Cyclophosphamide plus total body irradiation compared with busulfan plus cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplantation in patients with leukemia: a systematic review and meta-analysis. Hematol Oncol Stem Cell Ther. 2011, 4:17-29. 10.5144\/1658-3876.2011.17","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016004119","article-title":"ATG vs thiotepa with busulfan and cyclophosphamide in matched-related bone marrow transplantation for thalassemia","volume":"1","author":"Faulkner L","year":"2017","unstructured":"Faulkner L, Uderzo C, Khalid S, et al.. ATG vs thiotepa with busulfan and cyclophosphamide in matched-related bone marrow transplantation for thalassemia. Blood Adv. 2017, 1:792-801. 10.1182\/bloodadvances.2016004119","journal-title":"Blood Adv"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1007\/BF01834364","article-title":"Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for marrow transplantation: risk factors for early regimen-related toxicity","volume":"68","author":"Przepiorka D","year":"1994","unstructured":"Przepiorka D, Dimopoulos M, Smith T, Ippoliti C, Diener K, Luna M, Champlin RE. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for marrow transplantation: risk factors for early regimen-related toxicity. Ann Hematol. 1994, 68:183-8. 10.1007\/BF01834364","journal-title":"Ann Hematol"},{"key":"ref36","article-title":"Pharmacologically-guided dose adjustment of busulfan in high-dose chemotherapy regimens: rationale and pitfalls (review)","volume":"14","author":"Vassal G","year":"1994","unstructured":"Vassal G. Pharmacologically-guided dose adjustment of busulfan in high-dose chemotherapy regimens: rationale and pitfalls (review). Anticancer Res. 1994, 14:2363-70.","journal-title":"Anticancer Res"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2018.036","article-title":"Infectious complications after hematopoietic stem cell transplantation: current status and future perspectives in Korea","volume":"33","author":"Cho SY","year":"2018","unstructured":"Cho SY, Lee HJ, Lee DG. Infectious complications after hematopoietic stem cell transplantation: current status and future perspectives in Korea. Korean J Intern Med. 2018, 33:256-76. 10.3904\/kjim.2018.036","journal-title":"Korean J Intern Med"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201710-819OC","article-title":"Hospital volume of immunosuppressed patients with sepsis and sepsis mortality","volume":"15","author":"Greenberg JA","year":"2018","unstructured":"Greenberg JA, Hohmann SF, James BD, Shah RC, Hall JB, Kress JP, David MZ. Hospital volume of immunosuppressed patients with sepsis and sepsis mortality. Ann Am Thorac Soc. 2018, 15:962-9. 10.1513\/AnnalsATS.201710-819OC","journal-title":"Ann Am Thorac Soc"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-018-0435-0","article-title":"Rethinking antimicrobial prophylaxis in the transplant patient in the world of emerging resistant organisms-where are we today?","volume":"13","author":"Horton LE","year":"2018","unstructured":"Horton LE, Haste NM, Taplitz RA. Rethinking antimicrobial prophylaxis in the transplant patient in the world of emerging resistant organisms-where are we today?. Curr Hematol Malig Rep. 2018, 13:59-67. 10.1007\/s11899-018-0435-0","journal-title":"Curr Hematol Malig Rep"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/17.supplement_2.s359","article-title":"Prevention of infections in the neutropenic patient","volume":"17","author":"Verhoef J","year":"1993","unstructured":"Verhoef J. Prevention of infections in the neutropenic patient. Clin Infect Dis. 1993, 17:359-67. 10.1093\/clinids\/17.supplement_2.s359","journal-title":"Clin Infect Dis"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701746","article-title":"Influence of recombinant human granulocyte colony-stimulating factor (filgrastim) on hematopoietic recovery and outcome following allogeneic bone marrow transplantation (BMT) from volunteer unrelated donors","volume":"23","author":"Berger C","year":"1999","unstructured":"Berger C, Bertz H, Schmoor C, Behringer D, Potthoff K, Mertelsmann R, Finke J. Influence of recombinant human granulocyte colony-stimulating factor (filgrastim) on hematopoietic recovery and outcome following allogeneic bone marrow transplantation (BMT) from volunteer unrelated donors. Bone Marrow Transplant. 1999, 23:983-90. 10.1038\/sj.bmt.1701746","journal-title":"Bone Marrow Transplant"},{"key":"ref42","unstructured":"Cyclophosphamide prices, coupons and patient assistance programs. (2022). https.\/\/www.drugs.com\/price-guide\/cyclophosphamide."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/98857-assessing-the-efficacy-of-alkylating-agent-regimens-in-the-treatment-of-infantile-malignant-osteopetrosis-cyclophosphamide-busulfan-or-thiotepa","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:39:23Z","timestamp":1707507563000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/98857-assessing-the-efficacy-of-alkylating-agent-regimens-in-the-treatment-of-infantile-malignant-osteopetrosis-cyclophosphamide-busulfan-or-thiotepa"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,6]]},"references-count":42,"URL":"https:\/\/doi.org\/10.7759\/cureus.26600","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7,6]]}}}